BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:QXL138AM readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of QXL138AM\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06582017-3442@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:QXL138AM: Phase 1 readout est. (NCT06582017)
DESCRIPTION:QXL138AM\, phase 1\, Multiple Myeloma.\nStudy: Safety\, PK and 
 Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma\nE
 stimated primary completion: 31 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/qxl138am#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06582017
URL:https://assetmemo.bio/drug/qxl138am#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
